MIRXES-B (02629) announced its interim results for 2025, reporting revenue of US$10.5 million, representing a 9.4% year-on-year increase. The company recorded a net loss attributable to equity shareholders of approximately US$28.35 million, which narrowed by 36.22% compared to the same period last year. The loss per share was US$0.185.

According to the announcement, the year-on-year revenue growth was primarily driven by increased revenue from GASTROClearTM and LUNGClearTM products within the early detection and precision multi-omics division, which offset a US$2.6 million revenue decline in the infectious diseases division resulting from the discontinuation of FortitudeTM product sales.